Identifying the real-world challenges of dysplasia surveillance in inflammatory bowel disease: a retrospective cohort study in a tertiary health network

被引:2
|
作者
Elford, Alexander T. T. [1 ,2 ,4 ]
Hirsch, Ryan [1 ]
McKay, Owen M. M. [1 ]
Browne, Mitchell [1 ]
Moore, Gregory T. T. [1 ,3 ]
Bell, Sally [1 ,3 ]
Swan, Michael [1 ,3 ]
机构
[1] Monash Hlth, Melbourne, Vic, Australia
[2] Univ Melbourne, Melbourne, Vic, Australia
[3] Monash Univ, Melbourne, Vic, Australia
[4] Gastroenterol Dept, 300 Grattan St, Parkville, Vic 3050, Australia
关键词
inflammatory bowel disease; dysplasia; dye chromoendoscopy; PRIMARY SCLEROSING CHOLANGITIS; WHITE-LIGHT ENDOSCOPY; ULCERATIVE-COLITIS; COLORECTAL-CANCER; TARGETED BIOPSIES; RISK; COLONOSCOPY; NEOPLASIA; CHROMOENDOSCOPY; CARCINOMA;
D O I
10.1111/imj.16102
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundDysplasia surveillance in inflammatory bowel disease (IBD) is often suboptimal and deviates from guidelines. AimsTo assess dysplasia surveillance behaviours and adherence to guidelines amongst a large tertiary teaching health network with a specialised IBD unit to identify areas where dysplasia surveillance could be improved. MethodsA retrospective audit of IBD surveillance colonoscopy practice over an 18-month period was performed using the Provation Endoscopy Database and the hospital's primary sclerosing cholangitis database. ResultsThe audit identified 115 dysplasia surveillance colonoscopies. A total of 37% of index dysplasia colonoscopies were outside recommended guidelines. A total of 10% had inadequate bowel preparation and only 40% had excellent bowel preparation. A total of 28% of patients underwent dye-based chromoendoscopy and 69% underwent high-definition white-light endoscopy. Dye chromoendoscopy was more likely to be used by IBD specialists than interventional endoscopists (P = 0.008) and other endoscopists (P = 0.004). Only IBD specialists and interventional endoscopists used dye chromoendoscopy. Dysplasia or colorectal cancer was detected in 3.4% of the colonoscopies. Overall, the several dysplasia examinations were lower than expected. ConclusionsDysplasia surveillance in the IBD population remains an area of improvement given the current national guidelines. IBD specialists are more likely to perform dye chromoendoscopy than other endoscopists/gastroenterologists. Dysplasia rates in this real-world contemporary setting are less than expected in historical studies and may represent improvements in IBD management principles and medications.
引用
收藏
页码:96 / 103
页数:8
相关论文
共 50 条
  • [21] Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease
    Bressler, Brian
    Jones, Jennifer
    In, Tracy S. H.
    Lan, Tommy
    Iconaru, Cristian
    Marshall, John K.
    ADVANCES IN THERAPY, 2023, 40 (10) : 4421 - 4439
  • [22] REAL-WORLD USE OF PATIENT REPORTED OUTCOME MEASURES AT A LARGE TERTIARY INFLAMMATORY BOWEL DISEASE CENTER
    Sheehan, Jessica L.
    Johnson, Laura
    Cohen-Mekelburg, Shirley
    Higgins, Peter D.
    GASTROENTEROLOGY, 2024, 166 (05) : S533 - S534
  • [23] Effectiveness and safety of thiopurines in inflammatory bowel disease patients with NUDT15 polymorphism: a real-world retrospective study
    Chatterjee, Abhirup
    Bhatia, Prateek
    Sinha, Saroj K.
    Singh, Anupam K.
    Mandavdhare, Harshal S.
    Shah, Jimil
    Jearth, Vaneet
    Sasani, Arpit
    Sekar, Aravind
    Singh, Minu
    Dutta, Usha
    Sharma, Vishal
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2025, 18 (03) : 175 - 183
  • [24] DETECTING MUCOSAL AND POLYPOIDAL DYSPLASIS DURING SURVEILLANCE IN INFLAMMATORY BOWEL DISEASE: A RETROSPECTIVE COHORT STUDY
    King, Andrew
    Wyatt, Nicola
    Procter, Isabella
    Lamb, Christopher
    GASTROINTESTINAL ENDOSCOPY, 2024, 99 (06) : AB590 - AB590
  • [25] Vedolizumab clearance as a predictor of remission in inflammatory bowel disease: a real-world pharmacokinetic study
    Markovic, S.
    Kralj, D.
    Ivanovski, T. Knezevic
    Kalaba, A.
    Odanovic, O.
    Homsek, A.
    Svorcan, P.
    Vucicevic, K.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : I1231 - I1231
  • [26] Real-world patterns of dysplasia surveillance in inflammatory bowel disease: Observations from a single Australian center over successive 4-year periods
    Fang, W.
    Yeo, S. W.
    Garg, M.
    Van Langenberg, D.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 : 151 - 152
  • [27] Multiple infliximab biosimilar switches appear to be safe and effective in a real-world inflammatory bowel disease cohort
    Gros, Beatriz
    Plevris, Nikolas
    Constantine-Cooke, Nathan
    Lyons, Mathew
    O'Hare, Claire
    Noble, Colin
    Arnott, Ian D.
    Jones, Gareth-Rhys
    Lees, Charlie W.
    Derikx, Lauranne A. A. P.
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2023, : 179 - 188
  • [28] MULTIPLE INFLIXIMAB BIOSIMILAR SWITCHES APPEAR TO BE SAFE AND EFFECTIVE IN A REAL-WORLD INFLAMMATORY BOWEL DISEASE COHORT
    Gros, Beatriz
    Plevris, Nikolas
    Constantine-Cooke, Nathan
    Lyons, Mathew
    O'Hare, Claire
    Noble, Colin L.
    Arnott, Ian
    Jones, Gareth-Rhys
    Lees, Charlie W.
    Derikx, Lauranne
    GASTROENTEROLOGY, 2023, 164 (06) : S94 - S95
  • [29] REAL-WORLD RISKS OF SURGICAL INTERVENTIONS IN ELDERLY PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A POPULATION COHORT ANALYSIS
    Shah, Yash
    Burris, Victoria
    Shah, Vraj P.
    Weber, Andrew T.
    Patel, Dhruvan
    Lichtenstein, Gary R.
    GASTROENTEROLOGY, 2023, 164 (06) : S690 - S690
  • [30] Multiple infliximab biosimilar switches appear to be safe and effective in a real-world inflammatory bowel disease cohort
    Gros, B.
    Plevris, N.
    Constantine-Cooke, N.
    Lyons, M.
    O'Hare, C.
    Noble, C.
    Arnott, I. D.
    Jones, G. R.
    Lees, C. W.
    Derikx, L. A. A. P.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 876 - 876